

data_title_33253437 = """Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders
"""

data_abstract_33253437 = """
Objective
Some studies have linked the use of selective serotonin reuptake inhibitors and selective serotonin and noradrenaline reuptake inhibitors (SSRIs/SNRIs) to the risk of perinatal complications. This study explored the relationship between pharmacokinetics and pharmacogenetics, SSRIs/SNRIs tolerability and effectiveness and maternal and newborn outcomes.

Methods
Fifty-five pregnant women with Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnoses of affective disorders, treated with SSRIs/SNRIs, were recruited and, during the third trimester, their blood samples were collected for pharmacokinetic and pharmacogenetic analyses. Plasma levels and metabolic phenotypes were then related to different obstetrical and maternal outcomes.

Results
The pharmacokinetic data were more stable for Sertraline, Citalopram, and Escitalopram compared to other molecules (p = 0.009). The occurrence of postnatal adaptation syndrome onset was associated with higher plasma levels for Sertraline (median at delivery: 16.7 vs. 10.5 ng/ml), but not for fluoxetine and venlafaxine. Finally, the subgroup within range plasma concentrations had less blood loss than the below range subgroup (p = 0.030).

Conclusions
Plasma levels of Sertraline, Citalopram and Escitalopram were more frequently in range in late pregnancy when compared to other drugs. Drug plasma concentrations do not strictly correlate with worse perinatal outcomes, but with possible differences between the different drugs.
"""


data_caption_table_1_33253437 = """TABLE  2.
                    Individual pharmacokinetic, pharmacogenetic data and maternal/neonatal outcomes for women
Abbreviations: APGAR, Appearance, Pulse, Grimace, Activity, Respiration; CPAP, Continuous Positive Airway Pressure; EM, Extensive Metabolizer; GDM, Gestational Diabetes Mellitus; GH, gestational Hypertension; IM, Intermediate Metabolizer; NA, not available; NICU, Neonatal Intensive Care Unit; PL, Plasma Level; PROM, Premature Rupture of Membranes; PM, Poor Metabolizer; PPH, postpartum hemorrhage; RDS, Respiratory Distress Syndrome; RP, Rapid Metabolizer; SGA, Small for Gestational Age; UM, Ultrarapid Metabolizer.
[Correction added on December 5, 2020 after first online publication: The 8th column heading has been corrected. “CYP2C19” has been revised to “CYP2D6”.]"""

data_md_table_table_1_33253437 = """""
| Unnamed: 0 | ID | Dose (mg/d) | Mother's PL III trimester (ng/ml) | Mother's PL (ng/ml) delivery | Infant's PL (ng/ml) | Umbilical maternal ratio (%) | Other drugs | Expected phenotype (CYP2D6: major CYP metabolizer) | Maternal outcomes | Bleeding (ml) | Neonatal outcomes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sertraline | 1 | 75 | 19.5 | NA | NA | NA | - | UM | - | 250 | Apnea with desaturation and mild bradycardia, superficial breathing, polypnea at 48 h of life up to 5 day |
| Sertraline | 3 | 75 | 14.4 | 6.1 | <5 | 40.1 | - | IM | PROM | 400 | - |
| Sertraline | 4 | 150 | 25.7 | NA | 9 | NA | - | NA | - | 300 | Transient respiratory difficulty, mild irritability up to 48 h of life |
| Sertraline | 5 | 100 | 42.7 | 16.7 | 9.7 | 58.1 | - | PM | - | 100 | Tachypnea up to 48 h of life, SGA |
| Sertraline | 12 | 150 | 16.7 | 14.1 | <5 | 17.7 | - | EM | - | 400 | - |
| Sertraline | 13 | 75 | 26 | 12 | <5 | 20.8 | Phenobarbital | RM | - | 300 | SGA |
| Sertraline | 14 | 50 | 14.1 | 11.6 | <5 | 21.5 | - | IM | - | 500 | Left clubfoot |
| Sertraline | 15 | 100 | 27.4 | 42.6 | 19 | 44.6 | - | EM | - | 100 | Low apgar score 1′, RDS, hypotonus, SGA |
| Sertraline | 18 | 100 | 12.1 | NA | NA | NA | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir, Alafenamide; Zidovudine chemoprophylaxis during labour | UM | - | 500 | Low apgar score 1′, RDS (CPAP, transfer in NICU), SGA |
| Sertraline | 22 | 50 | NA | 24.5 | 11.1 | 45.3 | - | PM | - | 100 | RDS, neurologic symptom |
| Sertraline | 23 | 100 | NA | 9.2 | 6.5 | 70.6 | - | EM | - | 150 | - |
| Sertraline | 25 | 125 | NA | 89 | 35.5 | 39.9 | - | EM | - | 200 | - |
| Sertraline | 26 | 100 | NA | 32.7 | 7.8 | 23.8 | - | IM | PPH | 500 | - |
| Sertraline | 32 | 50 | NA | 12.7 | 13 | 102.4 | - | EM | - | 300 | - |
| Sertraline | 33 | 25 | NA | 9.5 | <5 | 26.3 | - | EM | - | 300 | - |
| Sertraline | 34 | 50 | NA | 7.4 | <5 | 33.8 | - | EM | - | 100 | - |
| Sertraline | 35 | 50 | NA | 7.8 | <5 | 32.0 | - | NA | - | 200 | - |
|  | 37 | 50 | NA | 16.9 | 8.2 | 48.5 | Levothyroxine | IM | - | 100 | - |
|  | 38 | 50 | NA | 9.5 | <5 | 26.6 | - | UM | - | 300 | - |
|  | 43 | 50 | 13.2 | 7.7 | 12.3 | 159.7 | - | NA | - | 100 | - |
|  | 46 | 50 | NA | 20 | 6 | 30.0 | Nifedipine | NA | GH | 800 | - |
|  | 48 | 50 | NA | 8.7 | 5 | 57.5 | - | NA | PPH | 1600 | - |
|  | 52 | 25 | <5 | <5 | <5 | NA | - | EM | PPH | 1500 | - |
|  | 53 | 50 | 13.1 | <5 | NA | NA | - | EM | PROM | 250 | Low apgar score 1′ and 5’; cyanosis, no spontaneous breathing (ventilation up to 24 h of life) |
| Citalopram | 36 | 20 | 90.2 | NA | NA | NA | - | EM | PROM, PPH | 1500 | - |
| Citalopram | 42 | 20 | 14.9 | 9.3 | 5.5 | 59.1 | Ursodeoxycholic acid | IM | Intrahepatic cholestasis | 250 | Neurologic symptom |
| Escitalopram | 9 | 5 | <5 | NA | NA | NA | - | IM | - | 250 | - |
| Escitalopram | 10 | 10 | 21.8 | 32.4 | 15.9 | 49.1 | - | NA | - | 600 | - |
| Escitalopram | 28 | 10 | NA | 10.1 | NA | NA | - | EM | - | 600 | - |
| Escitalopram | 29 | 10 | NA | <5 | NA | NA | - | IM | - | 900 | Neurologic symptom |
| Escitalopram | 30 | 10 | 68.8 | 36.5 | NA | NA | Ranitidine | IM | - | 100 | Low apgar score 1′, RDS, hypotonus SGA |
| Escitalopram | 47 | 5 | NA | 8.9 | 7.7 | 86.5 | - | NA | PROM | 500 | Bilateral hydronephrosis |
| Escitalopram | 56 | 10 | <5 | <5 | <5 | NA | - | EM | PROM | 150 | - |
| Escitalopram |  |  |  |  |  |  |  | Expected phenotype (CYP2D6: major CYP metabolizer) |  |  |  |
| Venlafaxine | 2 | 75 | 245 | 76.8 | 184.8 | 240.6 | - | NA | - | 400 | SGA |
| Venlafaxine | 6 | 375 | 37.6 | NA | NA | NA | Levothyroxine, Insulin | EM | GDM, PE, GH | 500 | Prematurity, left thumb bifid, low apgar score 1′ |
| Venlafaxine | 7 | 150 | NA | 179.9 | 234.7 | 13.5 | - | EM | PROM | 100 | - |
| Venlafaxine | 16 | 75 | 86.1 | NA | NA | NA | Levothyroxine | EM | PPH | 700 | Prematurity, macroglossia, transient hypoglycemia |
| Venlafaxine | 17 | 75 | 71.5 | NA | NA | NA | Insulin | EM | GDM | NA | - |
|  | 20 | 150 | NA | 199.8 | 78.9 | 39.5 | - | EM | - | 100 | Prematurity, low apgar score 1′ |
|  | 24 | 75 | 154.6 | NA | NA | NA | - | I/EM | PPH | 1100 | - |
| Paroxetine | 8 | 20 | 10.3 | NA | NA | NA | - | EM | PROM | 200 | SGA |
| Paroxetine | 19 | 20 | NA | 10 | NA | NA | Levothyroxine | EM | PROM | 600 | Risk of fetal distress (deep bradycardia), postpartum anemia, low apgar score 1′ |
| Paroxetine | 21 | 25 | NA | 23.4 | 9.1 | 38.9 | - | IM | - | 100 | Acrocyanosis at 8 h of life |
| Paroxetine | 31 | 20 | NA | 48.6 | 10.3 | 21.2 | - | I/EM | - | 300 | SGA, prematurity, low apgar score 1′, RDS, neurologic symptoms |
| Paroxetine | 45 | 20 | NA | <5 | <5 | NA | Levothroxine | NA | PPH | 1100 | BIlateral hydronephrosis |
| Paroxetine | 49 | 20 | <5 | <5 | NA | NA | - | EM | - | 300 | - |
| Paroxetine | 50 | 10 | 41.9 | 12.9 | 2.5 | 19.4 | - | PM | - | 100 | - |
| Paroxetine | 51 | 20 | <5 | <5 | <5 | NA | Levothiroxine | EM | PPH | 900 | - |
| Paroxetine | 54 | 10 | NA | <5 | <5 | NA | - | EM | - | 150 | - |
| Paroxetine | 55 | 20 | NA | <5 | <5 | NA | - | NA | - | 350 | SGA, Bicuspid aorta, hyper-excitability, bradycardia, desaturation, hypertonus, afinalistic sucking. Spontaneous resolution at 24 h of life |
| Paroxetine | 57 | 20 | NA | <5 | <5 | NA | - | NA | GDM, PROM, PPH | 1000 | - |
| Fluoxetine | 39 | 30 | 346.8 | NA | NA | NA | - | IM | PROM | NA | - |
| Fluoxetine | 40 | NA | NA | 147 | 152 | 103.4 | - | NA | Anhydramnios | 200 | - |
| Fluoxetine | 41 | NA | NA | <5 | <5 | NA | Insuline | NA | PROM | NA | Prematurity |
| Fluoxetine | 44 | 20 | NA | 216.8 | 108.6 | 50.1 | - | UM | - | 100 | SGA, Neonatal infection |
"""

data_md_table_drug_table_1_33253437 = """
| Drug name | Analyte | Specimen |
| --- | --- | --- |
| Sertraline | Sertraline | Plasma |
| Citalopram | Citalopram | Plasma |
| Escitalopram | Escitalopram | Plasma |
| Venlafaxine | Venlafaxine | Plasma |
| Paroxetine | Paroxetine | Plasma |
| Fluoxetine | Fluoxetine | Plasma |
"""

data_md_table_patient_table_1_33253437 = """
| Patient ID | Population | Pregnancy stage |
| --- | --- | --- |
| "1" | "N/A" | "N/A" |
| "3" | "N/A" | "N/A" |
| "4" | "N/A" | "N/A" |
| "5" | "N/A" | "N/A" |
| "12" | "N/A" | "N/A" |
| "13" | "N/A" | "N/A" |
| "14" | "N/A" | "N/A" |
| "15" | "N/A" | "N/A" |
| "18" | "N/A" | "N/A" |
| "22" | "N/A" | "N/A" |
| "23" | "N/A" | "N/A" |
| "25" | "N/A" | "N/A" |
| "26" | "N/A" | "N/A" |
| "32" | "N/A" | "N/A" |
| "33" | "N/A" | "N/A" |
| "34" | "N/A" | "N/A" |
| "36" | "N/A" | "N/A" |
| "42" | "N/A" | "N/A" |
| "9" | "N/A" | "N/A" |
| "10" | "N/A" | "N/A" |
| "28" | "N/A" | "N/A" |
| "29" | "N/A" | "N/A" |
| "30" | "N/A" | "N/A" |
| "47" | "N/A" | "N/A" |
| "56" | "N/A" | "N/A" |
| "2" | "N/A" | "N/A" |
| "6" | "N/A" | "N/A" |
| "7" | "N/A" | "N/A" |
| "16" | "N/A" | "N/A" |
| "17" | "N/A" | "N/A" |
| "20" | "N/A" | "N/A" |
| "24" | "N/A" | "N/A" |
| "8" | "N/A" | "N/A" |
| "19" | "N/A" | "N/A" |
| "21" | "N/A" | "N/A" |
| "31" | "N/A" | "N/A" |
| "45" | "N/A" | "N/A" |
| "49" | "N/A" | "N/A" |
| "50" | "N/A" | "N/A" |
| "51" | "N/A" | "N/A" |
| "39" | "N/A" | "N/A" |
| "40" | "N/A" | "N/A" |
| "41" | "N/A" | "N/A" |
| "44" | "N/A" | "N/A" |
| "46" | "N/A" | "N/A" |
| "52" | "N/A" | "N/A" |
| "53" | "N/A" | "N/A" |
| "54" | "N/A" | "N/A" |
| "55" | "N/A" | "N/A" |
"""

data_md_table_patient_refined_table_1_33253437 = """
| Patient ID | Population | Pregnancy stage | Pediatric/Gestational age |
| --- | --- | --- | --- |
| 1 | Maternal | Trimester 3 | N/A |
| 3 | Maternal | Trimester 3 | N/A |
| 4 | Maternal | Trimester 3 | N/A |
| 5 | Maternal | Trimester 3 | N/A |
| 12 | Maternal | Trimester 3 | N/A |
| 13 | Maternal | Trimester 3 | N/A |
| 14 | Maternal | Trimester 3 | N/A |
| 15 | Maternal | Trimester 3 | N/A |
| 18 | Maternal | Trimester 3 | N/A |
| 22 | Maternal | Trimester 3 | N/A |
| 23 | Maternal | Trimester 3 | N/A |
| 25 | Maternal | Trimester 3 | N/A |
| 26 | Maternal | Trimester 3 | N/A |
| 32 | Maternal | Trimester 3 | N/A |
| 33 | Maternal | Trimester 3 | N/A |
| 34 | Maternal | Trimester 3 | N/A |
| 36 | Maternal | Trimester 3 | N/A |
| 42 | Maternal | Trimester 3 | N/A |
| 9 | Maternal | Trimester 3 | N/A |
| 10 | Maternal | Trimester 3 | N/A |
| 28 | Maternal | Trimester 3 | N/A |
| 29 | Maternal | Trimester 3 | N/A |
| 30 | Maternal | Trimester 3 | N/A |
| 47 | Maternal | Trimester 3 | N/A |
| 56 | Maternal | Trimester 3 | N/A |
| 2 | Maternal | Trimester 3 | N/A |
| 6 | Maternal | Trimester 3 | N/A |
| 7 | Maternal | Trimester 3 | N/A |
| 16 | Maternal | Trimester 3 | N/A |
| 17 | Maternal | Trimester 3 | N/A |
| 20 | Maternal | Trimester 3 | N/A |
| 24 | Maternal | Trimester 3 | N/A |
| 8 | Maternal | Trimester 3 | N/A |
| 19 | Maternal | Trimester 3 | N/A |
| 21 | Maternal | Trimester 3 | N/A |
| 31 | Maternal | Trimester 3 | N/A |
| 45 | Maternal | Trimester 3 | N/A |
| 49 | Maternal | Trimester 3 | N/A |
| 50 | Maternal | Trimester 3 | N/A |
| 51 | Maternal | Trimester 3 | N/A |
| 39 | Maternal | Trimester 3 | N/A |
| 40 | Maternal | Trimester 3 | N/A |
| 41 | Maternal | Trimester 3 | N/A |
| 44 | Maternal | Trimester 3 | N/A |
| 46 | Maternal | Trimester 3 | N/A |
| 52 | Maternal | Trimester 3 | N/A |
| 53 | Maternal | Trimester 3 | N/A |
| 54 | Maternal | Trimester 3 | N/A |
| 55 | Maternal | Trimester 3 | N/A |
"""

data_md_table_individual_table_1_33253437 = """
| Unnamed: 0 | ID | Dose (mg/d) | Mother's PL III trimester (ng/ml) | Mother's PL (ng/ml) delivery | Infant's PL (ng/ml) | Umbilical maternal ratio (%) | Other drugs | Expected phenotype (CYP2D6: major CYP metabolizer) | Maternal outcomes | Bleeding (ml) | Neonatal outcomes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sertraline | 1 | 75 | 19.5 | NA | NA | NA | - | UM | - | 250 | Apnea with desaturation and mild bradycardia, superficial breathing, polypnea at 48 h of life up to 5 day |
| Sertraline | 3 | 75 | 14.4 | 6.1 | <5 | 40.1 | - | IM | PROM | 400 | - |
| Sertraline | 4 | 150 | 25.7 | NA | 9 | NA | - | NA | - | 300 | Transient respiratory difficulty, mild irritability up to 48 h of life |
| Sertraline | 5 | 100 | 42.7 | 16.7 | 9.7 | 58.1 | - | PM | - | 100 | Tachypnea up to 48 h of life, SGA |
| Sertraline | 12 | 150 | 16.7 | 14.1 | <5 | 17.7 | - | EM | - | 400 | - |
| Sertraline | 13 | 75 | 26 | 12 | <5 | 20.8 | Phenobarbital | RM | - | 300 | SGA |
| Sertraline | 14 | 50 | 14.1 | 11.6 | <5 | 21.5 | - | IM | - | 500 | Left clubfoot |
| Sertraline | 15 | 100 | 27.4 | 42.6 | 19 | 44.6 | - | EM | - | 100 | Low apgar score 1′, RDS, hypotonus, SGA |
| Sertraline | 18 | 100 | 12.1 | NA | NA | NA | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir, Alafenamide; Zidovudine chemoprophylaxis during labour | UM | - | 500 | Low apgar score 1′, RDS (CPAP, transfer in NICU), SGA |
| Sertraline | 22 | 50 | NA | 24.5 | 11.1 | 45.3 | - | PM | - | 100 | RDS, neurologic symptom |
| Sertraline | 23 | 100 | NA | 9.2 | 6.5 | 70.6 | - | EM | - | 150 | - |
| Sertraline | 25 | 125 | NA | 89 | 35.5 | 39.9 | - | EM | - | 200 | - |
| Sertraline | 26 | 100 | NA | 32.7 | 7.8 | 23.8 | - | IM | PPH | 500 | - |
| Sertraline | 32 | 50 | NA | 12.7 | 13 | 102.4 | - | EM | - | 300 | - |
| Sertraline | 33 | 25 | NA | 9.5 | <5 | 26.3 | - | EM | - | 300 | - |
| Sertraline | 34 | 50 | NA | 7.4 | <5 | 33.8 | - | EM | - | 100 | - |
| Sertraline | 35 | 50 | NA | 7.8 | <5 | 32.0 | - | NA | - | 200 | - |
|  | 37 | 50 | NA | 16.9 | 8.2 | 48.5 | Levothyroxine | IM | - | 100 | - |
|  | 38 | 50 | NA | 9.5 | <5 | 26.6 | - | UM | - | 300 | - |
|  | 43 | 50 | 13.2 | 7.7 | 12.3 | 159.7 | - | NA | - | 100 | - |
|  | 46 | 50 | NA | 20 | 6 | 30.0 | Nifedipine | NA | GH | 800 | - |
|  | 48 | 50 | NA | 8.7 | 5 | 57.5 | - | NA | PPH | 1600 | - |
|  | 52 | 25 | <5 | <5 | <5 | NA | - | EM | PPH | 1500 | - |
|  | 53 | 50 | 13.1 | <5 | NA | NA | - | EM | PROM | 250 | Low apgar score 1′ and 5’; cyanosis, no spontaneous breathing (ventilation up to 24 h of life) |
| Citalopram | 36 | 20 | 90.2 | NA | NA | NA | - | EM | PROM, PPH | 1500 | - |
| Citalopram | 42 | 20 | 14.9 | 9.3 | 5.5 | 59.1 | Ursodeoxycholic acid | IM | Intrahepatic cholestasis | 250 | Neurologic symptom |
| Escitalopram | 9 | 5 | <5 | NA | NA | NA | - | IM | - | 250 | - |
| Escitalopram | 10 | 10 | 21.8 | 32.4 | 15.9 | 49.1 | - | NA | - | 600 | - |
| Escitalopram | 28 | 10 | NA | 10.1 | NA | NA | - | EM | - | 600 | - |
| Escitalopram | 29 | 10 | NA | <5 | NA | NA | - | IM | - | 900 | Neurologic symptom |
| Escitalopram | 30 | 10 | 68.8 | 36.5 | NA | NA | Ranitidine | IM | - | 100 | Low apgar score 1′, RDS, hypotonus SGA |
| Escitalopram | 47 | 5 | NA | 8.9 | 7.7 | 86.5 | - | NA | PROM | 500 | Bilateral hydronephrosis |
| Escitalopram | 56 | 10 | <5 | <5 | <5 | NA | - | EM | PROM | 150 | - |
| Escitalopram |  |  |  |  |  |  |  | Expected phenotype (CYP2D6: major CYP metabolizer) |  |  |  |
| Venlafaxine | 2 | 75 | 245 | 76.8 | 184.8 | 240.6 | - | NA | - | 400 | SGA |
| Venlafaxine | 6 | 375 | 37.6 | NA | NA | NA | Levothyroxine, Insulin | EM | GDM, PE, GH | 500 | Prematurity, left thumb bifid, low apgar score 1′ |
| Venlafaxine | 7 | 150 | NA | 179.9 | 234.7 | 13.5 | - | EM | PROM | 100 | - |
| Venlafaxine | 16 | 75 | 86.1 | NA | NA | NA | Levothyroxine | EM | PPH | 700 | Prematurity, macroglossia, transient hypoglycemia |
| Venlafaxine | 17 | 75 | 71.5 | NA | NA | NA | Insulin | EM | GDM | NA | - |
|  | 20 | 150 | NA | 199.8 | 78.9 | 39.5 | - | EM | - | 100 | Prematurity, low apgar score 1′ |
|  | 24 | 75 | 154.6 | NA | NA | NA | - | I/EM | PPH | 1100 | - |
| Paroxetine | 8 | 20 | 10.3 | NA | NA | NA | - | EM | PROM | 200 | SGA |
| Paroxetine | 19 | 20 | NA | 10 | NA | NA | Levothyroxine | EM | PROM | 600 | Risk of fetal distress (deep bradycardia), postpartum anemia, low apgar score 1′ |
| Paroxetine | 21 | 25 | NA | 23.4 | 9.1 | 38.9 | - | IM | - | 100 | Acrocyanosis at 8 h of life |
| Paroxetine | 31 | 20 | NA | 48.6 | 10.3 | 21.2 | - | I/EM | - | 300 | SGA, prematurity, low apgar score 1′, RDS, neurologic symptoms |
| Paroxetine | 45 | 20 | NA | <5 | <5 | NA | Levothroxine | NA | PPH | 1100 | BIlateral hydronephrosis |
| Paroxetine | 49 | 20 | <5 | <5 | NA | NA | - | EM | - | 300 | - |
| Paroxetine | 50 | 10 | 41.9 | 12.9 | 2.5 | 19.4 | - | PM | - | 100 | - |
| Paroxetine | 51 | 20 | <5 | <5 | <5 | NA | Levothiroxine | EM | PPH | 900 | - |
| Paroxetine | 54 | 10 | NA | <5 | <5 | NA | - | EM | - | 150 | - |
| Paroxetine | 55 | 20 | NA | <5 | <5 | NA | - | NA | - | 350 | SGA, Bicuspid aorta, hyper-excitability, bradycardia, desaturation, hypertonus, afinalistic sucking. Spontaneous resolution at 24 h of life |
| Paroxetine | 57 | 20 | NA | <5 | <5 | NA | - | NA | GDM, PROM, PPH | 1000 | - |
| Fluoxetine | 39 | 30 | 346.8 | NA | NA | NA | - | IM | PROM | NA | - |
| Fluoxetine | 40 | NA | NA | 147 | 152 | 103.4 | - | NA | Anhydramnios | 200 | - |
| Fluoxetine | 41 | NA | NA | <5 | <5 | NA | Insuline | NA | PROM | NA | Prematurity |
| Fluoxetine | 44 | 20 | NA | 216.8 | 108.6 | 50.1 | - | UM | - | 100 | SGA, Neonatal infection |
"""

data_md_table_aligned_table_1_33253437 = """
| Unnamed: 0 | ID | Dose (mg/d) | Mother's PL III trimester (ng/ml) | Mother's PL (ng/ml) delivery | Infant's PL (ng/ml) | Umbilical maternal ratio (%) | Other drugs | Expected phenotype (CYP2D6: major CYP metabolizer) | Maternal outcomes | Bleeding (ml) | Neonatal outcomes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sertraline | 1 | 75 | 19.5 | NA | NA | NA | - | UM | - | 250 | Apnea with desaturation and mild bradycardia, superficial breathing, polypnea at 48 h of life up to 5 day |
| Sertraline | 3 | 75 | 14.4 | 6.1 | <5 | 40.1 | - | IM | PROM | 400 | - |
| Sertraline | 4 | 150 | 25.7 | NA | 9 | NA | - | NA | - | 300 | Transient respiratory difficulty, mild irritability up to 48 h of life |
| Sertraline | 5 | 100 | 42.7 | 16.7 | 9.7 | 58.1 | - | PM | - | 100 | Tachypnea up to 48 h of life, SGA |
| Sertraline | 12 | 150 | 16.7 | 14.1 | <5 | 17.7 | - | EM | - | 400 | - |
| Sertraline | 13 | 75 | 26 | 12 | <5 | 20.8 | Phenobarbital | RM | - | 300 | SGA |
| Sertraline | 14 | 50 | 14.1 | 11.6 | <5 | 21.5 | - | IM | - | 500 | Left clubfoot |
| Sertraline | 15 | 100 | 27.4 | 42.6 | 19 | 44.6 | - | EM | - | 100 | Low apgar score 1′, RDS, hypotonus, SGA |
| Sertraline | 18 | 100 | 12.1 | NA | NA | NA | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir, Alafenamide; Zidovudine chemoprophylaxis during labour | UM | - | 500 | Low apgar score 1′, RDS (CPAP, transfer in NICU), SGA |
| Sertraline | 22 | 50 | NA | 24.5 | 11.1 | 45.3 | - | PM | - | 100 | RDS, neurologic symptom |
| Sertraline | 23 | 100 | NA | 9.2 | 6.5 | 70.6 | - | EM | - | 150 | - |
| Sertraline | 25 | 125 | NA | 89 | 35.5 | 39.9 | - | EM | - | 200 | - |
| Sertraline | 26 | 100 | NA | 32.7 | 7.8 | 23.8 | - | IM | PPH | 500 | - |
| Sertraline | 32 | 50 | NA | 12.7 | 13 | 102.4 | - | EM | - | 300 | - |
| Sertraline | 33 | 25 | NA | 9.5 | <5 | 26.3 | - | EM | - | 300 | - |
| Sertraline | 34 | 50 | NA | 7.4 | <5 | 33.8 | - | EM | - | 100 | - |
| Sertraline | 35 | 50 | NA | 7.8 | <5 | 32.0 | - | NA | - | 200 | - |
|  | 37 | 50 | NA | 16.9 | 8.2 | 48.5 | Levothyroxine | IM | - | 100 | - |
|  | 38 | 50 | NA | 9.5 | <5 | 26.6 | - | UM | - | 300 | - |
|  | 43 | 50 | 13.2 | 7.7 | 12.3 | 159.7 | - | NA | - | 100 | - |
|  | 46 | 50 | NA | 20 | 6 | 30.0 | Nifedipine | NA | GH | 800 | - |
|  | 48 | 50 | NA | 8.7 | 5 | 57.5 | - | NA | PPH | 1600 | - |
|  | 52 | 25 | <5 | <5 | <5 | NA | - | EM | PPH | 1500 | - |
|  | 53 | 50 | 13.1 | <5 | NA | NA | - | EM | PROM | 250 | Low apgar score 1′ and 5’; cyanosis, no spontaneous breathing (ventilation up to 24 h of life) |
| Citalopram | 36 | 20 | 90.2 | NA | NA | NA | - | EM | PROM, PPH | 1500 | - |
| Citalopram | 42 | 20 | 14.9 | 9.3 | 5.5 | 59.1 | Ursodeoxycholic acid | IM | Intrahepatic cholestasis | 250 | Neurologic symptom |
| Escitalopram | 9 | 5 | <5 | NA | NA | NA | - | IM | - | 250 | - |
| Escitalopram | 10 | 10 | 21.8 | 32.4 | 15.9 | 49.1 | - | NA | - | 600 | - |
| Escitalopram | 28 | 10 | NA | 10.1 | NA | NA | - | EM | - | 600 | - |
| Escitalopram | 29 | 10 | NA | <5 | NA | NA | - | IM | - | 900 | Neurologic symptom |
| Escitalopram | 30 | 10 | 68.8 | 36.5 | NA | NA | Ranitidine | IM | - | 100 | Low apgar score 1′, RDS, hypotonus SGA |
| Escitalopram | 47 | 5 | NA | 8.9 | 7.7 | 86.5 | - | NA | PROM | 500 | Bilateral hydronephrosis |
| Escitalopram | 56 | 10 | <5 | <5 | <5 | NA | - | EM | PROM | 150 | - |
| Escitalopram |  |  |  |  |  |  |  | Expected phenotype (CYP2D6: major CYP metabolizer) |  |  |  |
| Venlafaxine | 2 | 75 | 245 | 76.8 | 184.8 | 240.6 | - | NA | - | 400 | SGA |
| Venlafaxine | 6 | 375 | 37.6 | NA | NA | NA | Levothyroxine, Insulin | EM | GDM, PE, GH | 500 | Prematurity, left thumb bifid, low apgar score 1′ |
| Venlafaxine | 7 | 150 | NA | 179.9 | 234.7 | 13.5 | - | EM | PROM | 100 | - |
| Venlafaxine | 16 | 75 | 86.1 | NA | NA | NA | Levothyroxine | EM | PPH | 700 | Prematurity, macroglossia, transient hypoglycemia |
| Venlafaxine | 17 | 75 | 71.5 | NA | NA | NA | Insulin | EM | GDM | NA | - |
|  | 20 | 150 | NA | 199.8 | 78.9 | 39.5 | - | EM | - | 100 | Prematurity, low apgar score 1′ |
|  | 24 | 75 | 154.6 | NA | NA | NA | - | I/EM | PPH | 1100 | - |
| Paroxetine | 8 | 20 | 10.3 | NA | NA | NA | - | EM | PROM | 200 | SGA |
| Paroxetine | 19 | 20 | NA | 10 | NA | NA | Levothyroxine | EM | PROM | 600 | Risk of fetal distress (deep bradycardia), postpartum anemia, low apgar score 1′ |
| Paroxetine | 21 | 25 | NA | 23.4 | 9.1 | 38.9 | - | IM | - | 100 | Acrocyanosis at 8 h of life |
| Paroxetine | 31 | 20 | NA | 48.6 | 10.3 | 21.2 | - | I/EM | - | 300 | SGA, prematurity, low apgar score 1′, RDS, neurologic symptoms |
| Paroxetine | 45 | 20 | NA | <5 | <5 | NA | Levothroxine | NA | PPH | 1100 | BIlateral hydronephrosis |
| Paroxetine | 49 | 20 | <5 | <5 | NA | NA | - | EM | - | 300 | - |
| Paroxetine | 50 | 10 | 41.9 | 12.9 | 2.5 | 19.4 | - | PM | - | 100 | - |
| Paroxetine | 51 | 20 | <5 | <5 | <5 | NA | Levothiroxine | EM | PPH | 900 | - |
| Paroxetine | 54 | 10 | NA | <5 | <5 | NA | - | EM | - | 150 | - |
| Paroxetine | 55 | 20 | NA | <5 | <5 | NA | - | NA | - | 350 | SGA, Bicuspid aorta, hyper-excitability, bradycardia, desaturation, hypertonus, afinalistic sucking. Spontaneous resolution at 24 h of life |
| Paroxetine | 57 | 20 | NA | <5 | <5 | NA | - | NA | GDM, PROM, PPH | 1000 | - |
| Fluoxetine | 39 | 30 | 346.8 | NA | NA | NA | - | IM | PROM | NA | - |
| Fluoxetine | 40 | NA | NA | 147 | 152 | 103.4 | - | NA | Anhydramnios | 200 | - |
| Fluoxetine | 41 | NA | NA | <5 | <5 | NA | Insuline | NA | PROM | NA | Prematurity |
| Fluoxetine | 44 | 20 | NA | 216.8 | 108.6 | 50.1 | - | UM | - | 100 | SGA, Neonatal infection |
"""

data_col_mapping_table_1_33253437 = {
    'Unnamed: 0': 'Uncategorized', 
    'ID': 'Patient ID', 
    'Dose (mg/d)': 'Uncategorized', 
    "Mother's PL III trimester (ng/ml)": 'Parameter value', 
    "Mother's PL (ng/ml) delivery": 'Parameter value', 
    "Infant's PL (ng/ml)": 'Parameter value', 
    'Umbilical maternal ratio (%)': 'Parameter value', 
    'Other drugs': 'Uncategorized', 
    'Expected phenotype (CYP2D6: major CYP metabolizer)': 'Uncategorized', 
    'Maternal outcomes': 'Uncategorized', 
    'Bleeding (ml)': 'Uncategorized', 
    'Neonatal outcomes': 'Uncategorized'
}

data_md_table_list_table_1_33253437 = ["""
| ID | Parameter type | Parameter value |
| --- | --- | --- |
| 1 | Mother's PL III trimester (ng/ml) | 19.5 |
| 3 | Mother's PL III trimester (ng/ml) | 14.4 |
| 4 | Mother's PL III trimester (ng/ml) | 25.7 |
| 5 | Mother's PL III trimester (ng/ml) | 42.7 |
| 12 | Mother's PL III trimester (ng/ml) | 16.7 |
| 13 | Mother's PL III trimester (ng/ml) | 26 |
| 14 | Mother's PL III trimester (ng/ml) | 14.1 |
| 15 | Mother's PL III trimester (ng/ml) | 27.4 |
| 18 | Mother's PL III trimester (ng/ml) | 12.1 |
| 22 | Mother's PL III trimester (ng/ml) | NA |
| 23 | Mother's PL III trimester (ng/ml) | NA |
| 25 | Mother's PL III trimester (ng/ml) | NA |
| 26 | Mother's PL III trimester (ng/ml) | NA |
| 32 | Mother's PL III trimester (ng/ml) | NA |
| 33 | Mother's PL III trimester (ng/ml) | NA |
| 34 | Mother's PL III trimester (ng/ml) | NA |
| 35 | Mother's PL III trimester (ng/ml) | NA |
| 37 | Mother's PL III trimester (ng/ml) | NA |
| 38 | Mother's PL III trimester (ng/ml) | NA |
| 43 | Mother's PL III trimester (ng/ml) | 13.2 |
| 46 | Mother's PL III trimester (ng/ml) | NA |
| 48 | Mother's PL III trimester (ng/ml) | NA |
| 52 | Mother's PL III trimester (ng/ml) | <5 |
| 53 | Mother's PL III trimester (ng/ml) | 13.1 |
| 36 | Mother's PL III trimester (ng/ml) | 90.2 |
| 42 | Mother's PL III trimester (ng/ml) | 14.9 |
| 9 | Mother's PL III trimester (ng/ml) | <5 |
| 10 | Mother's PL III trimester (ng/ml) | 21.8 |
| 28 | Mother's PL III trimester (ng/ml) | NA |
| 29 | Mother's PL III trimester (ng/ml) | NA |
| 30 | Mother's PL III trimester (ng/ml) | 68.8 |
| 47 | Mother's PL III trimester (ng/ml) | NA |
| 56 | Mother's PL III trimester (ng/ml) | <5 |
|  | Mother's PL III trimester (ng/ml) |  |
| 2 | Mother's PL III trimester (ng/ml) | 245 |
| 6 | Mother's PL III trimester (ng/ml) | 37.6 |
| 7 | Mother's PL III trimester (ng/ml) | NA |
| 16 | Mother's PL III trimester (ng/ml) | 86.1 |
| 17 | Mother's PL III trimester (ng/ml) | 71.5 |
| 20 | Mother's PL III trimester (ng/ml) | NA |
| 24 | Mother's PL III trimester (ng/ml) | 154.6 |
| 8 | Mother's PL III trimester (ng/ml) | 10.3 |
| 19 | Mother's PL III trimester (ng/ml) | NA |
| 21 | Mother's PL III trimester (ng/ml) | NA |
| 31 | Mother's PL III trimester (ng/ml) | NA |
| 45 | Mother's PL III trimester (ng/ml) | NA |
| 49 | Mother's PL III trimester (ng/ml) | <5 |
| 50 | Mother's PL III trimester (ng/ml) | 41.9 |
| 51 | Mother's PL III trimester (ng/ml) | <5 |
| 54 | Mother's PL III trimester (ng/ml) | NA |
| 55 | Mother's PL III trimester (ng/ml) | NA |
| 57 | Mother's PL III trimester (ng/ml) | NA |
| 39 | Mother's PL III trimester (ng/ml) | 346.8 |
| 40 | Mother's PL III trimester (ng/ml) | NA |
| 41 | Mother's PL III trimester (ng/ml) | NA |
| 44 | Mother's PL III trimester (ng/ml) | NA |
""", """
| ID | Parameter type | Parameter value |
| --- | --- | --- |
| 1 | Mother's PL (ng/ml) delivery | NA |
| 3 | Mother's PL (ng/ml) delivery | 6.1 |
| 4 | Mother's PL (ng/ml) delivery | NA |
| 5 | Mother's PL (ng/ml) delivery | 16.7 |
| 12 | Mother's PL (ng/ml) delivery | 14.1 |
| 13 | Mother's PL (ng/ml) delivery | 12 |
| 14 | Mother's PL (ng/ml) delivery | 11.6 |
| 15 | Mother's PL (ng/ml) delivery | 42.6 |
| 18 | Mother's PL (ng/ml) delivery | NA |
| 22 | Mother's PL (ng/ml) delivery | 24.5 |
| 23 | Mother's PL (ng/ml) delivery | 9.2 |
| 25 | Mother's PL (ng/ml) delivery | 89 |
| 26 | Mother's PL (ng/ml) delivery | 32.7 |
| 32 | Mother's PL (ng/ml) delivery | 12.7 |
| 33 | Mother's PL (ng/ml) delivery | 9.5 |
| 34 | Mother's PL (ng/ml) delivery | 7.4 |
| 35 | Mother's PL (ng/ml) delivery | 7.8 |
| 37 | Mother's PL (ng/ml) delivery | 16.9 |
| 38 | Mother's PL (ng/ml) delivery | 9.5 |
| 43 | Mother's PL (ng/ml) delivery | 7.7 |
| 46 | Mother's PL (ng/ml) delivery | 20 |
| 48 | Mother's PL (ng/ml) delivery | 8.7 |
| 52 | Mother's PL (ng/ml) delivery | <5 |
| 53 | Mother's PL (ng/ml) delivery | <5 |
| 36 | Mother's PL (ng/ml) delivery | NA |
| 42 | Mother's PL (ng/ml) delivery | 9.3 |
| 9 | Mother's PL (ng/ml) delivery | NA |
| 10 | Mother's PL (ng/ml) delivery | 32.4 |
| 28 | Mother's PL (ng/ml) delivery | 10.1 |
| 29 | Mother's PL (ng/ml) delivery | <5 |
| 30 | Mother's PL (ng/ml) delivery | 36.5 |
| 47 | Mother's PL (ng/ml) delivery | 8.9 |
| 56 | Mother's PL (ng/ml) delivery | <5 |
|  | Mother's PL (ng/ml) delivery |  |
| 2 | Mother's PL (ng/ml) delivery | 76.8 |
| 6 | Mother's PL (ng/ml) delivery | NA |
| 7 | Mother's PL (ng/ml) delivery | 179.9 |
| 16 | Mother's PL (ng/ml) delivery | NA |
| 17 | Mother's PL (ng/ml) delivery | NA |
| 20 | Mother's PL (ng/ml) delivery | 199.8 |
| 24 | Mother's PL (ng/ml) delivery | NA |
| 8 | Mother's PL (ng/ml) delivery | NA |
| 19 | Mother's PL (ng/ml) delivery | 10 |
| 21 | Mother's PL (ng/ml) delivery | 23.4 |
| 31 | Mother's PL (ng/ml) delivery | 48.6 |
| 45 | Mother's PL (ng/ml) delivery | <5 |
| 49 | Mother's PL (ng/ml) delivery | <5 |
| 50 | Mother's PL (ng/ml) delivery | 12.9 |
| 51 | Mother's PL (ng/ml) delivery | <5 |
| 54 | Mother's PL (ng/ml) delivery | <5 |
| 55 | Mother's PL (ng/ml) delivery | <5 |
| 57 | Mother's PL (ng/ml) delivery | <5 |
| 39 | Mother's PL (ng/ml) delivery | NA |
| 40 | Mother's PL (ng/ml) delivery | 147 |
| 41 | Mother's PL (ng/ml) delivery | <5 |
| 44 | Mother's PL (ng/ml) delivery | 216.8 |
""", """
| ID | Parameter type | Parameter value |
| --- | --- | --- |
| 1 | Infant's PL (ng/ml) | NA |
| 3 | Infant's PL (ng/ml) | <5 |
| 4 | Infant's PL (ng/ml) | 9 |
| 5 | Infant's PL (ng/ml) | 9.7 |
| 12 | Infant's PL (ng/ml) | <5 |
| 13 | Infant's PL (ng/ml) | <5 |
| 14 | Infant's PL (ng/ml) | <5 |
| 15 | Infant's PL (ng/ml) | 19 |
| 18 | Infant's PL (ng/ml) | NA |
| 22 | Infant's PL (ng/ml) | 11.1 |
| 23 | Infant's PL (ng/ml) | 6.5 |
| 25 | Infant's PL (ng/ml) | 35.5 |
| 26 | Infant's PL (ng/ml) | 7.8 |
| 32 | Infant's PL (ng/ml) | 13 |
| 33 | Infant's PL (ng/ml) | <5 |
| 34 | Infant's PL (ng/ml) | <5 |
| 35 | Infant's PL (ng/ml) | <5 |
| 37 | Infant's PL (ng/ml) | 8.2 |
| 38 | Infant's PL (ng/ml) | <5 |
| 43 | Infant's PL (ng/ml) | 12.3 |
| 46 | Infant's PL (ng/ml) | 6 |
| 48 | Infant's PL (ng/ml) | 5 |
| 52 | Infant's PL (ng/ml) | <5 |
| 53 | Infant's PL (ng/ml) | NA |
| 36 | Infant's PL (ng/ml) | NA |
| 42 | Infant's PL (ng/ml) | 5.5 |
| 9 | Infant's PL (ng/ml) | NA |
| 10 | Infant's PL (ng/ml) | 15.9 |
| 28 | Infant's PL (ng/ml) | NA |
| 29 | Infant's PL (ng/ml) | NA |
| 30 | Infant's PL (ng/ml) | NA |
| 47 | Infant's PL (ng/ml) | 7.7 |
| 56 | Infant's PL (ng/ml) | <5 |
|  | Infant's PL (ng/ml) |  |
| 2 | Infant's PL (ng/ml) | 184.8 |
| 6 | Infant's PL (ng/ml) | NA |
| 7 | Infant's PL (ng/ml) | 234.7 |
| 16 | Infant's PL (ng/ml) | NA |
| 17 | Infant's PL (ng/ml) | NA |
| 20 | Infant's PL (ng/ml) | 78.9 |
| 24 | Infant's PL (ng/ml) | NA |
| 8 | Infant's PL (ng/ml) | NA |
| 19 | Infant's PL (ng/ml) | NA |
| 21 | Infant's PL (ng/ml) | 9.1 |
| 31 | Infant's PL (ng/ml) | 10.3 |
| 45 | Infant's PL (ng/ml) | <5 |
| 49 | Infant's PL (ng/ml) | NA |
| 50 | Infant's PL (ng/ml) | 2.5 |
| 51 | Infant's PL (ng/ml) | <5 |
| 54 | Infant's PL (ng/ml) | <5 |
| 55 | Infant's PL (ng/ml) | <5 |
| 57 | Infant's PL (ng/ml) | <5 |
| 39 | Infant's PL (ng/ml) | NA |
| 40 | Infant's PL (ng/ml) | 152 |
| 41 | Infant's PL (ng/ml) | <5 |
| 44 | Infant's PL (ng/ml) | 108.6 |
""", """
| ID | Parameter type | Parameter value |
| --- | --- | --- |
| 1 | Umbilical maternal ratio (%) | NA |
| 3 | Umbilical maternal ratio (%) | 40.1 |
| 4 | Umbilical maternal ratio (%) | NA |
| 5 | Umbilical maternal ratio (%) | 58.1 |
| 12 | Umbilical maternal ratio (%) | 17.7 |
| 13 | Umbilical maternal ratio (%) | 20.8 |
| 14 | Umbilical maternal ratio (%) | 21.5 |
| 15 | Umbilical maternal ratio (%) | 44.6 |
| 18 | Umbilical maternal ratio (%) | NA |
| 22 | Umbilical maternal ratio (%) | 45.3 |
| 23 | Umbilical maternal ratio (%) | 70.6 |
| 25 | Umbilical maternal ratio (%) | 39.9 |
| 26 | Umbilical maternal ratio (%) | 23.8 |
| 32 | Umbilical maternal ratio (%) | 102.4 |
| 33 | Umbilical maternal ratio (%) | 26.3 |
| 34 | Umbilical maternal ratio (%) | 33.8 |
| 35 | Umbilical maternal ratio (%) | 32.0 |
| 37 | Umbilical maternal ratio (%) | 48.5 |
| 38 | Umbilical maternal ratio (%) | 26.6 |
| 43 | Umbilical maternal ratio (%) | 159.7 |
| 46 | Umbilical maternal ratio (%) | 30.0 |
| 48 | Umbilical maternal ratio (%) | 57.5 |
| 52 | Umbilical maternal ratio (%) | NA |
| 53 | Umbilical maternal ratio (%) | NA |
| 36 | Umbilical maternal ratio (%) | NA |
| 42 | Umbilical maternal ratio (%) | 59.1 |
| 9 | Umbilical maternal ratio (%) | NA |
| 10 | Umbilical maternal ratio (%) | 49.1 |
| 28 | Umbilical maternal ratio (%) | NA |
| 29 | Umbilical maternal ratio (%) | NA |
| 30 | Umbilical maternal ratio (%) | NA |
| 47 | Umbilical maternal ratio (%) | 86.5 |
| 56 | Umbilical maternal ratio (%) | NA |
|  | Umbilical maternal ratio (%) |  |
| 2 | Umbilical maternal ratio (%) | 240.6 |
| 6 | Umbilical maternal ratio (%) | NA |
| 7 | Umbilical maternal ratio (%) | 13.5 |
| 16 | Umbilical maternal ratio (%) | NA |
| 17 | Umbilical maternal ratio (%) | NA |
| 20 | Umbilical maternal ratio (%) | 39.5 |
| 24 | Umbilical maternal ratio (%) | NA |
| 8 | Umbilical maternal ratio (%) | NA |
| 19 | Umbilical maternal ratio (%) | NA |
| 21 | Umbilical maternal ratio (%) | 38.9 |
| 31 | Umbilical maternal ratio (%) | 21.2 |
| 45 | Umbilical maternal ratio (%) | NA |
| 49 | Umbilical maternal ratio (%) | NA |
| 50 | Umbilical maternal ratio (%) | 19.4 |
| 51 | Umbilical maternal ratio (%) | NA |
| 54 | Umbilical maternal ratio (%) | NA |
| 55 | Umbilical maternal ratio (%) | NA |
| 57 | Umbilical maternal ratio (%) | NA |
| 39 | Umbilical maternal ratio (%) | NA |
| 40 | Umbilical maternal ratio (%) | 103.4 |
| 41 | Umbilical maternal ratio (%) | NA |
| 44 | Umbilical maternal ratio (%) | 50.1 |
"""
]








